FMC - Friendship Manor is a medicare approved dialysis facility center in Roanoke, Virginia and it has 29 dialysis stations. It is located in Roanoke City county at Dialysis Unit, Roanoke, VA, 24012. You can reach out to the office of FMC - Friendship Manor at (540) 561-0870. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC - Friendship Manor has the following ownership type - Profit. It was first certified by medicare in October, 2000. The medicare id for this facility is 492610 and it accepts patients under medicare ESRD program.
| Name | FMC - Friendship Manor |
|---|---|
| Location | Dialysis Unit, Roanoke, Virginia |
| No. of Dialysis Stations | 29 |
| Medicare ID | 492610 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | Yes |
| Dialysis Unit, Roanoke, Virginia, 24012 | |
| (540) 561-0870 | |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
| NPI Number | 1265537542 |
| Organization Name | Fmc Dialysis Services Friendship Manor |
| Doing Business As | Bio-medical Applications Of Virginia, Inc. |
| Address | 331 Hershberger Rd Roanoke, Virginia, 24012 |
| Phone Number | (540) 561-0870 |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
| NPI Number | 1841515426 |
| Organization Name | Fmc Dialysis Services Friendship Manor |
| Doing Business As | Fresenius Medical Care Roanoke Valley Dialysis, Llc |
| Address | 331 Hershberger Rd Roanoke, Virginia, 24012 |
| Phone Number | (540) 561-0870 |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 61% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 21% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 18% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 53% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 14% |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 67% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 16% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 17% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 65% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 22% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 12% |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 81% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 19% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 78% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 7% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 12% |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 61 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 13 |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 135 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1065 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC - Friendship Manor with elevated calcium levels.
| Patients with hypercalcemia | 147 |
| Hypercalcemia patient months | 1162 |
| Patients with Serumphosphor | 165 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 31 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 36 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 17 |
| Patients with Serumphosphor greater than 7 mg/dL | 5 |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 132 |
| Patient months included in arterial venous fistula and catheter summaries | 904 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 70 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 10 |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 139 |
| Hospitalization Rate in facility | 200.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 300.6 |
| Hospitalization Rate: Lower Confidence Limit | 142.1 |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC - Friendship Manor were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 25.7 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 33.4 |
| Readmission Rate: Lower Confidence Limit | 18.4 |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC - Friendship Manor get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .64 (As Expected) |
| SIR: Upper Confidence Limit | 1.32 |
| SIR: Lower Confidence Limit | .26 |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC - Friendship Manor's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 103 |
| Transfusion Rate in facility | 43.6 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 84.9 |
| Transfusion Rate: Lower Confidence Limit | 24.2 |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC - Friendship Manor lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 584 |
| Mortality Rate in facility | 21.4 (Worse than Expected) |
| Mortality Rate: Upper Confidence Limit | 25.6 |
| Mortality Rate: Lower Confidence Limit | 17.7 |
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago
News Archive
Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.
Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company's outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.
A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.
For the study, the researchers reviewed 153 kidney biopsies in 126 patients. The researchers found that more than 60% of patients had a change in their treatment-whether surgery, tumor ablation, chemotherapy or radiation-due to biopsy results, and that as many as 75 unnecessary kidney removals were potentially avoided.
› Verified 9 days ago